Payment overview · 2025
General Payments
$627.71
16 reported records · 6 companies
Healthcare provider profile · identity verified
Alexandra Etkin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1932274156
Verified facts
What the public records show
CMS Open Payments records show Alexandra Etkin, M.D. received $627.71 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 65.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Ozempic, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $412.54 | 65.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.13 | 14.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.83 | 7.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.60 | 4.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.86 | 4.0% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $23.75 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.71 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $211.95 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $182.67 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.13 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.17 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $23.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 122 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 207 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
122 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
207 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
466 | 47 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
48 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 69 |
| Synthroid | Levothyroxine Sodium | 466 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 70 |
| Metformin Hcl | Metformin Hcl | 416 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 65 |
| Losartan Potassium | Losartan Potassium | 363 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 48 |
| Omeprazole | Omeprazole | 274 | 40 |
| Carvedilol | Carvedilol | 228 | 30 |
| Gabapentin | Gabapentin | 225 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 40 |
| Dexlansoprazole Dr | Dexlansoprazole | 207 | 21 |
| Linzess | Linaclotide | 207 | 27 |
| Trulicity | Dulaglutide | 201 | 20 |
| Celecoxib | Celecoxib | 194 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 20 |
| Enalapril Maleate | Enalapril Maleate | 180 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 21 |
| Furosemide | Furosemide | 155 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 22 |
| Atenolol | Atenolol | 143 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 83 |
| Azithromycin | Azithromycin | 128 | 90 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 124 | 25 |
| Creon | Lipase/Protease/Amylase | 122 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 15 |
| Jardiance | Empagliflozin | 112 | 13 |
| Zenpep | Lipase/Protease/Amylase | 103 | 16 |
| Vascepa | Icosapent Ethyl | 95 | suppressed |
| Lidocaine | Lidocaine | 93 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 88 | 14 |
| Eliquis | Apixaban | 88 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 15 |
| Donepezil Hcl | Donepezil Hcl | 82 | suppressed |
| Famotidine | Famotidine | 76 | suppressed |
| Glipizide | Glipizide | 74 | suppressed |
| Simvastatin | Simvastatin | 74 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 71 | suppressed |
| Glipizide Er | Glipizide | 70 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 16 |
| Meclizine Hcl | Meclizine Hcl | 65 | 15 |
| Allopurinol | Allopurinol | 64 | suppressed |
| Tradjenta | Linagliptin | 64 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 14 |
| Mometasone Furoate | Mometasone Furoate | 56 | 21 |
| Ramipril | Ramipril | 52 | suppressed |
| Proctozone-Hc | Hydrocortisone | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 49 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 49 | suppressed |
| Prolia | Denosumab | 48 | 33 |
| Procto-Med Hc | Hydrocortisone | 47 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 46 | suppressed |
| Mupirocin | Mupirocin | 46 | 15 |
| Cilostazol | Cilostazol | 44 | suppressed |
| Telmisartan | Telmisartan | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Dexilant | Dexlansoprazole | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 33 | 16 |
| Benicar | Olmesartan Medoxomil | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Lisinopril | Lisinopril | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Mupirocin | Mupirocin Calcium | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Edarbi | Azilsartan Medoxomil | 25 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | 11 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Bystolic | Nebivolol Hcl | 15 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Onglyza | Saxagliptin Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Terconazole | Terconazole | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Ztlido | Lidocaine | 14 | suppressed |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Norvasc | Amlodipine Besylate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vesicare | Solifenacin Succinate | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Etodolac Er | Etodolac | 12 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $627.71 · 16 records | ABBVIE INC. | ACCRUFER, CREON, ELIQUIS, EVENITY, LINZESS, NURTEC ODT, Ozempic, PANCREAZE, PROLIA, Rybelsus, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error